IL166625A0 - Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer - Google Patents

Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Info

Publication number
IL166625A0
IL166625A0 IL16662505A IL16662505A IL166625A0 IL 166625 A0 IL166625 A0 IL 166625A0 IL 16662505 A IL16662505 A IL 16662505A IL 16662505 A IL16662505 A IL 16662505A IL 166625 A0 IL166625 A0 IL 166625A0
Authority
IL
Israel
Prior art keywords
cancer
treatment
combination
tyrosine kinase
kinase inhibitors
Prior art date
Application number
IL16662505A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL166625A0 publication Critical patent/IL166625A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16662505A 2002-08-09 2005-02-01 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer IL166625A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218526.2A GB0218526D0 (en) 2002-08-09 2002-08-09 Combination therapy
PCT/GB2003/003390 WO2004014426A1 (en) 2002-08-09 2003-08-05 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Publications (1)

Publication Number Publication Date
IL166625A0 true IL166625A0 (en) 2006-01-15

Family

ID=9942013

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16662505A IL166625A0 (en) 2002-08-09 2005-02-01 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Country Status (14)

Country Link
US (2) US20050245549A1 (enExample)
EP (1) EP1534338A1 (enExample)
JP (1) JP2006500346A (enExample)
KR (1) KR20050059060A (enExample)
CN (1) CN100556456C (enExample)
BR (1) BR0313117A (enExample)
CA (1) CA2495489A1 (enExample)
GB (1) GB0218526D0 (enExample)
IL (1) IL166625A0 (enExample)
MX (1) MXPA05001457A (enExample)
NO (1) NO20050528L (enExample)
NZ (1) NZ537754A (enExample)
WO (1) WO2004014426A1 (enExample)
ZA (1) ZA200501061B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
IL151626A0 (en) 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
EP2292615A1 (en) 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
JP2007526886A (ja) * 2003-07-10 2007-09-20 アストラゼネカ アクチボラグ 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
AU2006236940A1 (en) * 2005-04-14 2006-10-26 Wyeth Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
CA2663599A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
SI2451445T1 (sl) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2002223684A1 (en) * 2000-11-22 2002-06-03 Novartis Pharma Gmbh Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
CA2482591A1 (en) * 2002-04-16 2003-10-30 Astrazeneca Ab Combination therapy for the treatment of cancer
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
JP2007526886A (ja) * 2003-07-10 2007-09-20 アストラゼネカ アクチボラグ 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed

Also Published As

Publication number Publication date
CN1674938A (zh) 2005-09-28
JP2006500346A (ja) 2006-01-05
MXPA05001457A (es) 2005-06-06
CN100556456C (zh) 2009-11-04
NZ537754A (en) 2008-02-29
GB0218526D0 (en) 2002-09-18
CA2495489A1 (en) 2004-02-19
NO20050528L (no) 2005-05-03
US20050245549A1 (en) 2005-11-03
BR0313117A (pt) 2005-07-05
EP1534338A1 (en) 2005-06-01
AU2003252976A1 (en) 2004-02-25
WO2004014426A1 (en) 2004-02-19
ZA200501061B (en) 2007-01-31
US20100130493A1 (en) 2010-05-27
KR20050059060A (ko) 2005-06-17

Similar Documents

Publication Publication Date Title
ZA200306125B (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
IL198996A0 (en) Inhibitors of tyrosine kinases
PL1686999T3 (pl) Pochodne pirazolowe jako inhibitory receptorowych kinaz tyrozynowych
PT1667991E (pt) Derivados de quinazolina como inibidores da tirosina cinase
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
AU2003282891A8 (en) Novel tyrosine kinases inhibitors
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
IL173593A0 (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
EP1581539A4 (en) NEW TYROSINE KINASE HEMMER
SI1531819T1 (sl) Uporaba IxB-kinaznih inhibitorjev pri terapiji bolečin
AU2003273842A8 (en) Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibitors
AU2003275282A8 (en) Novel tyrosine kinase inhibitors
SI1610780T2 (sl) Inhibitorji ciklične proteintirozin kinaze
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
IL183448A0 (en) Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
IL173483A0 (en) Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases
SI1562955T1 (sl) Derivati kinazolina kot inhibitorji Src-triozin kinaze
SI1660090T1 (sl) Kinazolinski analogi kot inhibitorji receptorjev tirozin kinaze
HK1076745A (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
GB2410744B (en) Kinase inhibitors for the treatment of disease
AU2003219420A1 (en) Pdgf receptor tyrosine kinase inhibitors for the treatment of polycythemia vera
GB0201384D0 (en) Tyrosine kinase inhibitors
SI1478380T1 (sl) Uporaba inhibitorjev tirozin kinaze za zdravljenje bolezni CZS